Nonacus Galeas uPCR ESR1 Assay

Nonacus has launched a research-use-only qPCR kit to detect ESR1 mutations. The Galeas uPCR ESR1 kit is an ultrasensitive qPCR assay developed to detect eleven mutations in the ESR1 gene known to be associated with resistance to endocrine therapy, a common treatment for certain types of breast cancer. uPCR is a novel method developed by Nonacus that increases the sensitivity and specificity of mutation detection for qPCR but does not require an investment in special equipment, the company said.